Skip to Content

Rolapitant Dosage

Medically reviewed on January 18, 2018.

Applies to the following strengths: 90 mg; 166.5 mg/92.5 mL

Usual Adult Dose for Nausea/Vomiting - Chemotherapy Induced

180 mg orally approximately 1 to 2 hours prior to initiation of each chemotherapy cycle.

Comments: Dexamethasone and a 5-HT3 receptor antagonist should be administered concurrently with rolapitant. Consult manufacturer product information for appropriate dosing information for these drugs.

Use: In combination with other antiemetic agents for prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.

Renal Dose Adjustments

-Mild to Moderate Renal Dysfunction (CrCl 30 to 90 mL/min): Data not available; however, pharmacokinetics were not significantly affected in patients with this level of renal impairment.
-Severe Renal Dysfunction (CrCl less than 30 mL/min): Data not available.

Liver Dose Adjustments

-Mild to Moderate Liver Impairment (Child-Pugh A and B): No adjustment recommended.
-Severe Liver Impairment (Child-Pugh C): Avoid use; monitor patients for adverse reactions if use cannot be avoided.


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available.

Other Comments

Administration Advice:
-This drug should be administered at no less than 2 week intervals.
-This drug can be administered without regard to meals.

-There is no antidote for overdose with this drug; treatment should be discontinued and general supportive measures/close observation instituted in the event of overdose.
-Animal studies did not reveal any drug-related neoplastic findings at doses up to 4.9 times the recommended human dose.

Patient Advice:
-Do not take this drug more than one time every 14 days.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.